tradingkey.logo

Eton Pharmaceuticals Inc

ETON
View Detailed Chart
16.900USD
-2.240-11.70%
Close 11/07, 16:00ETQuotes delayed by 15 min
453.22MMarket Cap
LossP/E TTM

Eton Pharmaceuticals Inc

16.900
-2.240-11.70%
Intraday
1m
30m
1h
D
W
M
D

Today

-11.70%

5 Days

-6.16%

1 Month

-19.25%

6 Months

-2.48%

Year to Date

+26.88%

1 Year

+92.48%

View Detailed Chart

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Eton Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking
63 / 159
Overall Ranking
176 / 4614
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 3 analysts
Buy
Current Rating
30.000
Target Price
+77.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Eton Pharmaceuticals Inc Highlights

StrengthsRisks
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 83.57% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 39.01M.
Fairly Valued
The company’s latest PE is -67.89, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 16.70M shares, increasing 3.38% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.34M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.64.

Eton Pharmaceuticals Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Eton Pharmaceuticals Inc Info

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
CompanyEton Pharmaceuticals Inc
CEOMr. Sean E. Brynjelsen
Websitehttps://etonpharma.com/
KeyAI